SymBio Pharmaceuticals Limited (4582.T)
JPY 212.0
(-1.85%)
JPY 212.0
(-1.85%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -1.96 Billion JPY | -266.45% |
| 2022 | 1.17 Billion JPY | -41.97% |
| 2021 | 2.03 Billion JPY | 149.68% |
| 2020 | -4.09 Billion JPY | 6.54% |
| 2019 | -4.37 Billion JPY | -58.99% |
| 2018 | -2.75 Billion JPY | 30.8% |
| 2017 | -3.97 Billion JPY | -71.96% |
| 2016 | -2.31 Billion JPY | 12.11% |
| 2015 | -2.63 Billion JPY | -135.88% |
| 2014 | -1.11 Billion JPY | 30.48% |
| 2013 | -1.6 Billion JPY | 7.39% |
| 2012 | -1.73 Billion JPY | 17.64% |
| 2011 | -2.1 Billion JPY | -227.65% |
| 2010 | -642.3 Million JPY | -194.81% |
| 2009 | -217.87 Million JPY | -1138.13% |
| 2008 | 20.98 Million JPY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -777.39 Million JPY | 33.79% |
| 2024 Q3 | -1.3 Billion JPY | -70.65% |
| 2024 Q2 | -763.94 Million JPY | 1.73% |
| 2023 Q4 | -1.17 Billion JPY | -65.63% |
| 2023 Q1 | 4.45 Million JPY | 101.18% |
| 2023 FY | -1.96 Billion JPY | -266.45% |
| 2023 Q2 | -84.3 Million JPY | -1992.37% |
| 2023 Q3 | -708.86 Million JPY | -740.83% |
| 2022 Q4 | -376.5 Million JPY | -184.11% |
| 2022 FY | 1.17 Billion JPY | -41.97% |
| 2022 Q1 | 163.17 Million JPY | -90.44% |
| 2022 Q2 | 944.92 Million JPY | 479.1% |
| 2022 Q3 | 447.65 Million JPY | -52.63% |
| 2021 Q3 | 530.41 Million JPY | 12840.11% |
| 2021 Q1 | -209.65 Million JPY | 84.98% |
| 2021 FY | 2.03 Billion JPY | 149.68% |
| 2021 Q4 | 1.7 Billion JPY | 221.89% |
| 2021 Q2 | 4.09 Million JPY | 101.96% |
| 2020 FY | -4.09 Billion JPY | 6.54% |
| 2020 Q2 | -892.8 Million JPY | 10.01% |
| 2020 Q1 | -992.17 Million JPY | -34.86% |
| 2020 Q3 | -809.3 Million JPY | 9.35% |
| 2020 Q4 | -1.39 Billion JPY | -72.48% |
| 2019 Q3 | -1.57 Billion JPY | -8.1% |
| 2019 Q2 | -1.45 Billion JPY | -135.51% |
| 2019 FY | -4.37 Billion JPY | -58.99% |
| 2019 Q4 | -735.7 Million JPY | 53.16% |
| 2019 Q1 | -616.95 Million JPY | 23.99% |
| 2018 Q4 | -811.69 Million JPY | -46.95% |
| 2018 FY | -2.75 Billion JPY | 30.8% |
| 2018 Q1 | -759.69 Million JPY | -75.92% |
| 2018 Q2 | -628.81 Million JPY | 17.23% |
| 2018 Q3 | -552.34 Million JPY | 12.16% |
| 2017 Q3 | -2.27 Billion JPY | -233.49% |
| 2017 FY | -3.97 Billion JPY | -71.96% |
| 2017 Q1 | -582.76 Million JPY | -46.63% |
| 2017 Q2 | -683.57 Million JPY | -17.3% |
| 2017 Q4 | -431.84 Million JPY | 81.06% |
| 2016 FY | -2.31 Billion JPY | 12.11% |
| 2016 Q4 | -397.43 Million JPY | 46.33% |
| 2016 Q1 | -652.63 Million JPY | 58.5% |
| 2016 Q2 | -522.7 Million JPY | 19.91% |
| 2016 Q3 | -740.45 Million JPY | -41.66% |
| 2015 Q1 | -420.49 Million JPY | -144.16% |
| 2015 Q3 | -383 Million JPY | -49.65% |
| 2015 FY | -2.63 Billion JPY | -135.88% |
| 2015 Q4 | -1.57 Billion JPY | -310.62% |
| 2015 Q2 | -255.92 Million JPY | 39.14% |
| 2014 Q3 | -228.29 Million JPY | 12.36% |
| 2014 FY | -1.11 Billion JPY | 30.48% |
| 2014 Q4 | -172.22 Million JPY | 24.56% |
| 2014 Q2 | -260.5 Million JPY | 42.73% |
| 2014 Q1 | -454.85 Million JPY | -9.74% |
| 2013 Q2 | -460.75 Million JPY | -30.39% |
| 2013 Q3 | -376.62 Million JPY | 18.26% |
| 2013 Q4 | -414.46 Million JPY | -10.05% |
| 2013 FY | -1.6 Billion JPY | 7.39% |
| 2013 Q1 | -353.37 Million JPY | 25.4% |
| 2012 Q3 | -361.95 Million JPY | 5.05% |
| 2012 Q4 | -473.67 Million JPY | -30.86% |
| 2012 FY | -1.73 Billion JPY | 17.64% |
| 2012 Q1 | -516.45 Million JPY | -56.8% |
| 2012 Q2 | -381.23 Million JPY | 26.18% |
| 2011 Q1 | -399.07 Million JPY | 0.0% |
| 2011 Q2 | -308.26 Million JPY | 22.76% |
| 2011 Q3 | -1.06 Billion JPY | -246.39% |
| 2011 Q4 | -329.36 Million JPY | 69.16% |
| 2011 FY | -2.1 Billion JPY | -227.65% |
| 2010 Q4 | - JPY | 0.0% |
| 2010 Q2 | - JPY | 0.0% |
| 2010 FY | -642.3 Million JPY | -194.81% |
| 2009 Q4 | - JPY | 0.0% |
| 2009 FY | -217.87 Million JPY | -1138.13% |
| 2008 FY | 20.98 Million JPY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 3.2 Billion JPY | 161.242% |
| Takeda Pharmaceutical Company Limited | 144.06 Billion JPY | 101.362% |
| Sumitomo Pharma Co., Ltd. | -314.96 Billion JPY | 99.377% |
| Shionogi & Co., Ltd. | 162.03 Billion JPY | 101.211% |
| Wakamoto Pharmaceutical Co.,Ltd. | 108.95 Million JPY | 1901.427% |
| Nippon Shinyaku Co., Ltd. | 25.85 Billion JPY | 107.593% |
| Kaken Pharmaceutical Co., Ltd. | 8.02 Billion JPY | 124.459% |
| Eisai Co., Ltd. | 42.4 Billion JPY | 104.629% |
| Morishita Jintan Co., Ltd. | 697 Million JPY | 381.609% |
| Hisamitsu Pharmaceutical Co., Inc. | 13.96 Billion JPY | 114.051% |
| Mochida Pharmaceutical Co., Ltd. | 4.54 Billion JPY | 143.167% |
| Fuso Pharmaceutical Industries,Ltd. | 1.37 Billion JPY | 242.543% |
| Nippon Chemiphar Co., Ltd. | -180 Million JPY | -990.454% |
| Tsumura & Co. | 16.7 Billion JPY | 111.748% |
| Kissei Pharmaceutical Co., Ltd. | 11.16 Billion JPY | 117.588% |
| Torii Pharmaceutical Co., Ltd. | 4.11 Billion JPY | 147.653% |
| Towa Pharmaceutical Co., Ltd. | 16.17 Billion JPY | 112.136% |
| Fuji Pharma Co., Ltd. | 3.43 Billion JPY | 157.142% |
| Zeria Pharmaceutical Co., Ltd. | 7.73 Billion JPY | 125.388% |
| KYORIN Holdings, Inc. | 5.32 Billion JPY | 136.881% |
| Taiko Pharmaceutical Co.,Ltd. | -4.89 Billion JPY | 59.893% |
| Daito Pharmaceutical Co.,Ltd. | 3.29 Billion JPY | 159.57% |
| MedRx Co., Ltd | -932 Million JPY | -110.603% |
| Mizuho Medy Co.,Ltd. | 3.77 Billion JPY | 152.006% |
| Solasia Pharma K.K. | -1.11 Billion JPY | -76.512% |
| Modalis Therapeutics Corporation | -2.39 Billion JPY | 17.936% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 7.54 Billion JPY | 126.015% |
| Sawai Group Holdings Co., Ltd. | 13.69 Billion JPY | 114.332% |
| Cyfuse Biomedical K.K. | -589.21 Million JPY | -233.126% |
| Toho Holdings Co., Ltd. | 20.65 Billion JPY | 109.502% |
| Koa Shoji Holdings Co.,Ltd. | 2.94 Billion JPY | 166.619% |